Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Abstract Background: Venetoclax has shown promising activity when combined with hypomethylating agents (HMAs) and low-dose cytarabine (LDAC) with response rates in the range of 75% in untreated patients ≥65 years with acute myeloid leukemia (AML). [DiNardo C, ASH 2015 Abstract 327 Pfizer: Research Funding; Genentech: Research Funding. Horvat: Agios: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Mauro: Bristol-Myers Squibb: Consultancy. Stein: Constellation Pharma: Research Funding; Pfizer: Consultancy, Other: Travel expenses; Seattle Genetics: Research Funding; GSK: Other: Advisory Board, Research Funding; Novartis: Consultancy, Research Funding; Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Celgene Corporation: Consultancy, Other: Travel expenses, Research Funding.